Icu Medical Inc/De (ICUI) Stock Price & Analysis
Icu Medical Inc/De (ICUI) rose 3.29% to USD 142 as of June 10, 2026 at 02:33 UTC, according to Nexqual real-time market data.
ICUI last closed at USD 137.48; the session ranged USD 138.58–142.36 on volume of 271,185 shares. Market capitalization is $3.55B, with a 52-week range of USD 107–160.29 (NMS). Source: Nexqual, June 10, 2026 at 02:33 UTC.
Key Statistics (as of June 10, 2026 at 02:33 UTC)
| Price | USD 142 |
|---|---|
| Change | ▲ 3.29% (up) |
| Previous Close | USD 137.48 |
| Open | USD 138.73 |
| Day Range | USD 138.58 – 142.36 |
| 52-Week Range | USD 107 – 160.29 |
| Volume | 271,185 shares |
| Market Cap | $3.55B |
| Exchange | NMS |
Technical Analysis (ICUI)
Nexqual's technical model rates ICUI "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.49 (neutral) |
| vs SMA50 | Above (USD 126.84) |
| MACD | 3.37 (positive) |
Analyst Ratings (ICUI)
Wall Street analysts rate ICUI "Buy" based on 7 analysts, with a mean price target of USD 172.86 (range USD 160–200), per Nexqual as of June 10, 2026 at 02:33 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 172.86 |
| High Target | USD 200 |
| Low Target | USD 160 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (ICUI)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.91 |
| Revenue Estimate | $534.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.97 vs est 1.75 ▲ beat |
| 2025-12-31 | USD 1.91 vs est 1.69 ▲ beat |
| 2025-09-30 | USD 2.03 vs est 1.43 ▲ beat |
| 2025-06-30 | USD 2.1 vs est 1.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Financials & Fundamentals (ICUI)
| Total Revenue | $2.16B |
|---|---|
| Revenue Growth (YoY) | -12.30% |
| Gross Margin | +37.93% |
| Operating Margin | +5.73% |
| Profit Margin | +2.15% |
| ROE | +2.26% |
| Debt / Equity | 63.62 |
| Current Ratio | 2.34 |
| Total Cash | $292.68M |
| Total Debt | $1.34B |
| Free Cash Flow | $387.08M |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Financial Health Score (ICUI)
Nexqual rates Icu Medical Inc/De's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:33 UTC.
| Growth | Weak — Revenue -7% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 38%, operating 6% |
| Balance Sheet | Strong — $293M cash vs $1.34B debt |
| Cash Flow | Strong — FCF $387M, 17% margin |
| Efficiency | Weak — ROE 2%, ROA 1.7% |
Ownership (ICUI)
| Insider Ownership | +3.80% |
|---|---|
| Institutional Ownership | +113.70% |
| Shares Outstanding | 24.99M |
| Float | 24.51M |
| Short % of Float | +8.81% |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Leadership (ICUI)
Icu Medical Inc/De is led by Vivek Jain (age 53), CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 02:33 UTC.
| CEO & Chairman of the Board | Vivek Jain (age 53) |
|---|---|
| President | Daniel Woolson (age 48) |
| CFO & Treasurer | Brian Michael Bonnell (age 51) |
| Chief Operating Officer | Christian B. Voigtlander (age 57) |
| Vice President of Human Resources | Olivia Barrall |
Major Backers & Investors (ICUI)
Notable institutional backers of Icu Medical Inc/De include Janus Henderson Group PLC, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, Fuller & Thaler Asset Management Inc., according to Nexqual as of June 10, 2026 at 02:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 10.71% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.4% |
| Fuller & Thaler Asset Management Inc. | 4.88% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.01% |
| Schroder Investment Management Group | 2.81% |
| River Road Asset Management, LLC | 2.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 22.77% |
| Vanguard Group | 18.2% |
| Dimensional Fund Advisors | 3.94% |
| State Street | 3.87% |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
From Icu Medical Inc/De's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Our primary Infusion System products are: Large Volume Pump ("LVP") Hardware: • Plum Duo™ and Plum Solo™ precision infusion pumps (together, the "Plum precision pumps") are single-channel and dual-channel infusion pump systems that received FDA 510(k) clearance in April 2025.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MMSI | Merit Medical Systems, Inc. | USD 67.51 | ▲ 4.7% |
| HAE | Haemonetics Corporation | USD 78.71 | ▲ 10.42% |
| IART | Integra LifeSciences Holdings C | USD 17.9 | ▲ 5.36% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:33 UTC. This page is informational and not investment advice.